$2.27
+0.27%
N/A+$0.01
헬스케어
의료 - 기기
NASDAQ
활발히 거래 중
Pulmonx Corporation은 만성 폐쇄성 폐질환을 관리하기 위한 고급의 덜 침습적인 기기를 개발하고 상용화하는 데 전념하는 생의학 기술 기업입니다. 주요 제품인 Zephyr Endobronchial ...
Pulmonx Corporation은 만성 폐쇄성 폐질환을 관리하기 위한 고급의 덜 침습적인 기기를 개발하고 상용화하는 데 전념하는 생의학 기술 기업입니다. 주요 제품인 Zephyr Endobronchial ...
Pulmonx Corporation is a commercial-stage medical technology company headquartered in Redwood City, California, dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases, particularly severe emphysema. Its flagship product, the Zephyr Endobronchial Valve, is a minimally invasive, one-time procedure performed via bronchoscopy to treat bronchoscopic hyperinflation in adults with severe emphysema. The company also offers the Chartis Pulmonary Assessment System, which uses a specialized balloon catheter and console to measure collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that provides quantitative CT analysis for treatment planning. Pulmonx serves patients across the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. With over 40,000 patients treated, the company has established itself as a leader in interventional pulmonology. Financially, Pulmonx generates revenue primarily from the sale of these devices and services, with a gross profit margin of 77.1% but currently operating at a loss due to high R&D and SG&A expenses. The company went public in October 2020 and has a market cap of approximately $95 million. Key leadership includes CEO Glendon E. French, who has over 30 years of experience in medical devices, though recent announcements indicate a transition to Steve Williamson as the new President and CEO. The company continues to invest heavily in research and development to expand its product portfolio and improve patient outcomes, with a focus on innovation and global expansion.